Evidence map›Paper›PMID 41395557›Full record

ArticleInternational cancer conference journal2025

Successful treatment of primary intramedullary spinal cord lymphoma based on the molecular diagnosis of a MYD88 mutation in the cerebrospinal fluid: a case report.

Takuma Aoki, Makoto Ohno, Shunsuke Yanagisawa, Daisuke Kawauchi, Takaki Omura, Akiya Kawanishi, Mai Honda-Kitahara, Yoshitaka Narita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takuma AokiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Makoto OhnoDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Shunsuke YanagisawaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Daisuke KawauchiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Takaki OmuraDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Akiya KawanishiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Mai Honda-KitaharaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary intramedullary spinal cord lymphoma (PISCL) is a rare subtype of primary central nervous system lymphoma (PCNSL) that mimics other myelopathies, often leading to delayed diagnosis. Histopathological confirmation via spinal biopsy is the gold standard; however, spinal biopsies carry considerable risks. The

Indexed as

Cerebrospinal fluidLiquid biopsyMYD88 L265P mutationPrimary intramedullary spinal cord lymphoma

Identifiers

PMID41395557
PMCPMC12696207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.